2026年1月,诺纳生物科学社加入中国联盟,利用合作研究及其港口Mice 技术进行快速免疫治疗。 In Jan 2026, Nona Biosciences joined a Chinese alliance to fast-track immunology therapies using collaborative research and its Harbour Mice® tech.

2026年1月,Nona生物科学社在中国共同创立了“免疫疾病翻译医学创新联盟”,将临床专家、机构和生物制药公司联合起来,加速免疫疾病研究。 In January 2026, Nona Biosciences co-founded the "Innovative Alliance for Translational Medicine in Immunological Diseases" in China, uniting clinical experts, institutions, and biopharmaceutical companies to accelerate research on immunological diseases. 该联盟将重点关注由研究人员发起的试验, 通过10到20种治疗候选药物在三年内实现概念验证. The alliance will focus on investigator-initiated trials to advance 10 to 20 therapeutic candidates to proof-of-concept within three years. 作为核心成员,诺娜将利用该平台查明未得到满足的临床需求,利用其港口Mice技术加快治疗发展,强调协作将科学发现与现实世界治疗连接起来。 As a core member, Nona will use the platform to identify unmet clinical needs and leverage its Harbour Mice® technology to speed therapy development, emphasizing collaboration to bridge scientific discovery and real-world treatment.